Iron status and survival in diabetic patients with coronary artery disease

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 4147-4156

  Ponikowska, Beata ^a   Suchocki, Tomasz ^b   Paleczny, Bartłomiej ^a   Olesinska, Martyna ^a,c   Powierza, Slawomir ^c   Borodulin Nadzieja, Ludmila ^a   Reczuch, Krzysztof ^a,c   Haehling, Stephan Von ^d   Doehner, Wolfram ^d   Anker, Stefan D ^d   Cleland, John G F ^e   Jankowska, Ewa A ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^c MILITARY HOSPITAL   (Poland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; GLUCOSE; INSULIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DIABETIC PATIENT; EVENT FREE SURVIVAL; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH IMPACT ASSESSMENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SURVIVAL; SURVIVAL RATE; TRANSFERRIN BLOOD LEVEL; TRANSFERRIN SATURATION; BLOOD; COMPLICATION; EPIDEMIOLOGY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PHOTOMETRY; POLAND; PROGNOSIS; TIME; TRENDS;

AGED; BIOMARKERS; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IRON; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; POLAND; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84891859325     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0528     Document Type: Article

References (52)

1. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2
2. Tussing-Humphreys L, Pusatcioglu C, Nemeth E, Braunschweig C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J Acad Nutr Diet 2012;112:391-400
3. Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 2013;43:215-224
4. Varma A, Appleton DL, Nusca A, et al. Iron deficiency anemia and cardiac mortality in patients with left ventricular systolic dysfunction undergoing coronary stenting. Minerva Cardioangiol 2010;58: 1-10
5. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1880
6. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011;17: 899-906
7. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816-829
8. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-723
9. Utzschneider KM, Kowdley KV. Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice. Nat Rev Endocrinol 2010;6:26-33
10. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370:511-520
11. Haas JD, Brownlie T 4th. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131(2S-2):676S-688S; discussion 688S-690S
12. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(Suppl. 2): 568S-579S; discussion 580S
13. Rouault TA, Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 2005; 6:345-351
14. Chen C, Paw BH. Cellular and mitochondrial iron homeostasis in vertebrates. Biochim Biophys Acta 2012;1823:1459-1467
15. Walter PB, Knutson MD, Paler-Martinez A, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA 2002; 99:2264-2269
16. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:92-103
17. Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic b cells. Trends Endocrinol Metab 2012;23: 477-487
18. Hashimoto K, Osugi T, Noguchi S, et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care 2010;33:509-511
19. Fox K, Garcia MA, Ardissino D, et al.; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381
20. Blanc B, Finch CA, Hallberg L. Nutritional anemias. Report of a WHO Scientific Group. Geneva, World Health Org. (Tech. Rep. Ser., 1968;405:1-40)
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495
23. Therneau TM, Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York, NY, Springer, 2001
24. Anderson DR. Model Based Inference in the Life Sciences. New York, NY, Springer, 2008
25. R Development Core Team. R: A language and environment for statistical computing, 2010. Vienna, Austria, R Foundation for Statistical Computing. Available at http://www.R-project.org. Accessed 15 February 2013
26. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010;142:24-38
27. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116:4754-4761
28. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1(Suppl. 1): S4-S8
29. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008;111:3373-3376
30. Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 2009;18:345-352
31. Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83:872-875
32. Hardikar PS, Joshi SM, Bhat DS, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young Indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care 2012;35:797-802
33. Friedrich N, Milman N, Völzke H, Linneberg A, Jørgensen T. Is serum ferritin within the reference range a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 subjects. Br JNutr 2009;102: 594-600
34. Hsu HS, Li CI, Liu CS, et al. Iron deficiency is associated with increased risk for cardiovascular disease and all-cause mortality in the elderly living in long-term care facilities. Nutrition 2013;29:737-743
35. Corti MC, Guralnik JM, Salive ME, et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 1997;79:120-127
36. Casiglia E, Tikhonoff V, Bascelli A, et al. Dietary iron intake and cardiovascular outcome in Italian women: 10-year followup. J Womens Health (Larchmt) 2011;20: 1565-1571
37. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. Am J Epidemiol 1996;144:59-68
38. Kim KS, Son HG, Hong NS, Lee DH. Associations of serum ferritin and transferrin% saturation with all-cause, cancer, and cardiovascular disease mortality: Third National Health and Nutrition Examination Survey follow-up study. J Prev Med Pub Health 2012;45:196-203
39. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;330:1119-1124
40. Mørkedal B, Laugsand LE, Romundstad PR, Vatten LJ. Mortality from ischaemic heart disease: sex-specific effects of transferrin saturation, serum iron, and total iron binding capacity. The HUNT study. Eur J Cardiovasc Prev Rehabil 2011;18:687-694
41. Sempos CT, Looker AC, Gillum RE, McGee DL, Vuong CV, Johnson CL. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol 2000;10:441-448
42. Menke A, Muntner P, Fernández-Real JM, Guallar E. The association of biomarkers of iron status with mortality in US adults. Nutr Metab Cardiovasc Dis 2012;22:734-740
43. van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665-670
44. Reunanen A, Takkunen H, Knekt P, Seppänen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995;238: 223-230
45. Zhang W, Iso H, Ohira T, et al. Associations of dietary iron intake with mortality from cardiovascular disease: the JACC study. J Epidemiol 2012;22:484-493
46. Wells BJ, Mainous AG 3rd, King DE, Gill JM, Carek PJ, Geesey ME. The combined effect of transferrin saturation and low density lipoprotein on mortality. Fam Med 2004;36:324-329
47. Steen DL, Cannon CP, Lele SS, et al. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol 2013;36:139-145
48. Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J 2013;34: 827-834
49. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575-582, e3
50. De Lima GA, Mazzali M, Gentil AF, Plotegher L, Grotto HZ. Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolismin patients not submitted to dialysis treatment. Clin Lab 2012;58: 695-704
51. Anker SD, Comin Colet J, Filippatos G, et al.; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448
52. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-112